inflammation

two arrows pointing different directions

Avere goes public via reverse merger, pays $120M for Hansoh drug

Avere burst onto the scene by securing a public listing via a reverse merger with NextCure, while stocking its pipeline with an IL-23 drug from Hansoh.

Will Maddox Jul 14, 2026 6:00am

Spero pivots to I&I via $1.1B deal with Innovent antibody

Jul 14, 2026 6:00am

Bionyra emerges with $165M and three licensed I&I assets

Jun 22, 2026 7:00am

BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions

May 22, 2026 10:00am

BioAge CEO's big plans for 'multi-disease impact' of NLRP3 drug

May 14, 2026 11:00am

Four white arrows pointing to computer trash can icon

Boehringer, Amgen scrap immunology assets, citing low potential

Apr 14, 2026 4:00am